NCT00352339

The New Strategy for Pharmacological Treatment in People With Schizophrenia

Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Inje University · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.

Detailed description

It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces long term adverse events of drug such as TD, osteoporosis and some metabolic syndrome. To overcome these adverse events, new strategy for pharmacological treatment is needed.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Rispridoen and Aripiprazole	Start with risperidone and switch it to aripiprazole. Flexible dose
DRUG	Risperidne	Start with risperidne and keep it through the end of study. Risperidne:flexible dose
DRUG	Abilify	Start with abilify and keep it through the end of study

Timeline

• Start date: 2006-08-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2006-07-14
• Last updated: 2009-08-06

Locations

2 sites across 1 country: South Korea